| Bioactivity | UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD)[1]. |
| Invitro | UK‑396082 (0-1000 nM; NRK52E 细胞; 96 小时) 以剂量依赖性方式诱导 TAFI 活性[1]。UK‑396082 (500 nM; 24 h) 增加 NRK52E 细胞 (+109%) 和 NRK49F 成纤维细胞 (+38.3%) 中的纤溶酶活性[1]。UK‑396082 (500 nM; 24 h; NRK52E 细胞) 使 ECM 水平降低 46%[1]。 |
| Name | UK‑396082 |
| CAS | 400044-47-5 |
| Formula | C12H21N3O2 |
| Molar Mass | 239.31 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Atkinson JM, et, al. An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion. Matrix Biol. 2013 Jun 24;32(5):277-87. |